Astellas Gene Therapies is exploring three gene therapy modalities: gene replacement, exon skipping gene therapy, and vectorized RNA knockdown for targeted therapies. As of January 2026, instead of developing the AAV-based resamirigene bilparvovec (AT132) on its own, Astellas is partnering with Kate Therapeutics—acquired in 2024 by Novartis for up to $1.1 billion—to develop a MyoAAV capsid-based gene therapy for XLMTM.
Cyborg Score Rationale
Astellas Gene Therapies demonstrates solid clinical and operational infrastructure with a $100M manufacturing facility and a multi-modal AAV gene therapy platform targeting rare diseases. However, data limitations and lack of publicly disclosed revenue or recent milestone announcements temper confidence. Strategic partnerships and active clinical programs offset execution risks.
Top Insights
Astellas Gene Therapies is consolidating gene therapy production at its $100 million biomanufacturing facility in Sanford, North Carolina, having closed its South San Francisco site, signaling manufacturing optimization and operational consolidation as the company advances its pipeline.
The company's lead candidate drug is AT132 for the treatment of X-Linked Myotubular Myopathy. The broader disorder pipeline includes Pompe disease, Friedreich ataxia, myotonic dystrophy type 1 and X-linked myotubular myopathy.
As of January 2026, Astellas partnered with Kate Therapeutics (acquired by Novartis for up to $1.1 billion) to develop a MyoAAV capsid-based therapy for XLMTM, indicating strategic reliance on third-party capsid innovations to advance its core program.
Named Competitors
Onpattro (patisiran) — RNAi therapeutics for rare genetic diseases including hereditary transthyretin amyloidosis
Gene therapy platform — Gene therapies and genomic medicines for rare genetic diseases
Luxturna (voretigene neparvovec) — AAV gene therapy for inherited retinal dystrophies and other rare diseases
Recent Developments
(January 2026) Astellas partnered with Kate Therapeutics to develop MyoAAV capsid-based gene therapy for XLMTM
(September 2024) Closed South San Francisco production facility and consolidated manufacturing to Sanford, North Carolina
(October 2025) Option Agreement with Taysha Gene Therapies expired; Astellas did not exercise GAN or Rett options
Open the full interactive Astellas Gene Therapies, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.